Crinetics Pharmaceuticals, Inc.
CRNX
Kedudukan dalam Saham
#2246
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Harga Saham
$84.95
Disegerakkan terakhir: 2026-09-01
Modal Pasaran
$9.00B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
98.25%
Negara
US
Perdagangan Crinetics Pharmaceuticals, Inc. (CRNX)
Kategori
Healthcare
Pendapatan untuk Crinetics Pharmaceuticals, Inc. (CRNX)
Pendapatan pada Jun 2026 TTM: $-501.43M
Menurut laporan kewangan terkini Crinetics Pharmaceuticals, Inc., pendapatan semasa syarikat ialah $-501.43M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-214.53M, penurunan berbanding pendapatan pada tahun 2022 yang berjumlah $-163.92M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Crinetics Pharmaceuticals, Inc. dari 2016 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-501.43M | 68.03% |
| 2024 | $-298.41M | 39.10% |
| 2023 | $-214.53M | 30.88% |
| 2022 | $-163.92M | 52.28% |
| 2021 | $-107.64M | 45.83% |
| 2020 | $-73.81M | 46.39% |
| 2019 | $-50.42M | 85.96% |
| 2018 | $-27.12M | 196.11% |
| 2017 | $-9.16M | 52.13% |
| 2016 | $-6.02M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -1,151.98% |
US
|
|
| $-3.09B | 515.64% |
US
|
|
| $-4.02B | 700.95% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -489.02% |
NL
|
